Chardan Capital reiterated their neutral rating on shares of Vistagen Therapeutics (NASDAQ:VTGN) in a research report released on Monday morning, Zacks.com reports.
VTGN has been the subject of a number of other research reports. Maxim Group set a $6.00 price target on Vistagen Therapeutics and gave the stock a buy rating in a research report on Thursday, May 2nd. Zacks Investment Research cut Vistagen Therapeutics from a buy rating to a hold rating in a research report on Saturday, May 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $3.55.
VTGN opened at $0.51 on Monday. Vistagen Therapeutics has a 1 year low of $0.38 and a 1 year high of $2.44. The company’s fifty day moving average price is $0.67.
About Vistagen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Featured Story: Strangles
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.